Context Therapeutics Files Q1 2025 10-Q
Ticker: CNTX · Form: 10-Q · Filed: May 7, 2025 · CIK: 1842952
| Field | Detail |
|---|---|
| Company | Context Therapeutics Inc. (CNTX) |
| Form Type | 10-Q |
| Filed Date | May 7, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, financials, pharmaceuticals
TL;DR
Context Therapeutics Q1 2025 10-Q is in. Financials for stock, capital, and retained earnings are updated.
AI Summary
Context Therapeutics Inc. filed its 10-Q for the period ending March 31, 2025. The company, focused on pharmaceutical preparations, reported its financial status for the first quarter of 2025. Key financial data related to common stock, additional paid-in capital, and retained earnings were disclosed for the periods ending March 31, 2025, December 31, 2024, and December 31, 2023.
Why It Matters
This filing provides investors with the latest financial snapshot of Context Therapeutics, crucial for understanding the company's financial health and operational status in the pharmaceutical sector.
Risk Assessment
Risk Level: low — This is a routine financial filing (10-Q) that provides standard financial disclosures and does not contain significant new risk factors.
Key Numbers
- 20250331 — Reporting Period End Date (Indicates the end of the fiscal quarter for which financial information is reported.)
- 20250507 — Filing Date (The date the 10-Q was officially submitted to the SEC.)
- 2024-12-31 — Previous Year End Date (Provides a comparative point for financial performance.)
Key Players & Entities
- Context Therapeutics Inc. (company) — Filer of the 10-Q
- 20250331 (date) — End of the reporting period
- 20250507 (date) — Filing date
- 2834 (other) — Standard Industrial Classification for Pharmaceutical Preparations
- 2001 MARKET STREET (location) — Company's business and mailing address
- PHILADELPHIA (location) — Company's city
- DE (location) — State of incorporation
FAQ
What is the primary business of Context Therapeutics Inc. according to the filing?
Context Therapeutics Inc. is classified under Standard Industrial Classification 2834, which pertains to Pharmaceutical Preparations.
For what period is the financial information presented in this 10-Q report?
The 10-Q report covers the period ending March 31, 2025.
When was this 10-Q filing submitted to the SEC?
The filing was submitted on May 7, 2025.
What are the key financial components for which data is provided across different periods?
The filing provides data for Common Stock, Additional Paid-In Capital, and Retained Earnings for the periods ending March 31, 2025, December 31, 2024, and December 31, 2023.
Where is Context Therapeutics Inc. headquartered?
The company's business and mailing address is listed as 2001 Market Street, Suite 3915, Unit #15, Philadelphia, PA 19103.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 7, 2025 regarding Context Therapeutics Inc. (CNTX).